Mark is an experienced venture capital investor, with significant experience as a board director of both private and public biotech companies in the US and Europe. He is currently a managing director at Arix Bioscience and a board director of Harpoon Therapeutics (Nasdaq: HARP), Imara (Nasdaq: IMRA), Iterum Therapeutics (Nasdaq: ITRM), and a number of privately held biotechnology companies.
Prior to Arix, Mark was a principal at Longitude Capital, where he focused on investments in biotechnology and medical technology companies. Prior to Longitude, he was a consultant at the Boston Consulting Group, where he was responsible for strategy and corporate development projects for pharmaceutical and biotechnology companies. Before BCG, he worked in corporate development at Gilead Sciences and market planning at Genentech. He has an MBA from The Wharton School at the University of Pennsylvania, an MS in Biotechnology from the University of Pennsylvania, and a BS in Management Science from the University of California at San Diego.